Table I.
Patient clinical and pathological characteristics.
| No. of patients (%) | |
|---|---|
| Age (years) | |
| Median | 53 |
| Range | 32–75 |
| Menopausal status | |
| Pre-menopause | 21 (43.8) |
| Postmenopause | 27 (56.3) |
| Tumor stage | |
| 0 | 1 (2.1) |
| 1 | 5 (10.4) |
| 2 | 31 (64.6) |
| 3 | 6 (12.5) |
| 4 | 5 (10.4) |
| Nodal stage | |
| N0 | 29 (60.5) |
| N1 | 17 (35.5) |
| N2 | 1 (2.0) |
| Unknown | 1 (2.0) |
| Nuclear grade | |
| 1 | 12 (25.0) |
| 2 | 10 (20.8) |
| 3 | 26 (54.2) |
| ER | |
| Positive | 28 (58.3) |
| Negative | 20 (41.7) |
| PR | |
| Positive | 16 (33.3) |
| Negative | 32 (66.7) |
| HER2 (IHC) | |
| 0 | 12 (25.0) |
| 1+ | 22 (45.8) |
| 2+ | 6 (12.5) |
| 3+ | 7 (14.6) |
| Unknown | 1 (2.1) |
| Subtypes of breast cancer | |
| Luminal A | 8 (16.7) |
| Luminal B | 20 (41.7) |
| HER2+ | 5 (10.3) |
| Triple negative | 15 (31.3) |
| Pathological response | |
| Grade 0 | 3 (6.3) |
| Grade 1a | 22 (45.8) |
| Grade 1b | 10 (20.8) |
| Grade 2 | 6 (12.5) |
| Grade 3 | 5 (10.4) |
| Unknown | 2 (4.2) |
Pathological response defined as grade 0, no chemotherapeutic change in remnant cancer cells; grade 1a, 0–1/3 of remnant cancer cells in degeneration or necrosis; grade 1b, 1/3–2/3; grade 2, >2/3; grade 3, no viable cancer cells in duct and stroma. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor-2; IHC, immunohistochemistry.